Citeline Podcasts

Audio roundup of selected biopharma industry content from Scrip over the business week ended June 12, 2026. This episode was produced with the help of AI text-to-voice and voice emulation tools. This time–Lilly explores Zepbound in autoimmune disorders; AstraZeneca pursues interconnected strategy in CVRM; AstraZeneca moving oral GLP-1 into Phase III; Boehringer pursues quality weight loss with sur...

Flagship Pioneering의 안드레 안도니안 아시아태평양 의장과 이병건 한국 담당 특별고문은 Scrip과의 인터뷰에서 새로운 파트너십을 모색하고, 자사의 기업 설립 모델을 국내 바이오 생태계에 적용하는 등 한국 시장 진출 전략을 공유했습니다.(AI 기반 텍스트 음성 변환 및 음성 모방 도구의 도움을 받아 제작되었습니다) Story link: https://insights.citeline.com/scrip/leadership/interviews/flagship-eyes-long-term-partn...

本期播客内容来自《Scrip》杂志，精选内容涵盖截至2026年6月5日当周的生物制药行业的商业动态。本期节目采用人工智能文本转语音及语音仿真技术制作。 本期要闻: Revolution公司的daraxonrasib在ASCO大会上引发轰动；默克公司（Merck & Co.）阐述其肿瘤学愿景；美国立法者对中美交易感到不满；ADA大会上的肥胖症治疗新挑战；以及2025年大型制药公司CEO薪酬回升。 Story links: https://insights.citeline.com/scrip/podcasts/scrips...

Audio roundup of selected biopharma industry content from Scrip over the business week ended May 29, 2026. This episode was produced with the help of AI text-to-voice and voice emulation tools. This time – can GLP-1s help in cancer; Novartis on its cardiovascular strategy; Lilly’s retatrutide looks promising in obesity; Lilly’s raises cell and gene therapy bet; and the business impact of China’s n...

Audio roundup of selected biopharma industry content from Scrip over the business week ended June 5, 2026. This episode was produced with the help of AI text-to-voice and voice emulation tools. This time – Revolution’s daraxonrasib makes splash at ASCO; Merck & Co. lays out oncology vision; US legislators bristle over US-China deals; obesity challengers at ADA; and big pharma CEO pay rebounds in 2...

Pink Sheet Executive Editor Derrick Gingery, Senior Reporter Maaisha Osman, Senior Editor Sue Sutter and Editor-in-Chief Nielsen Hobbs, as well as Generics Bulletin Executive Editor David Wallace, consider the implications of the US Supreme Court decision upholding the skinny labeling system (:37), including how the generic industry will adapt going forward (9:02). They also discuss the stakeholde...

本期播客内容来自《Scrip》杂志，精选内容涵盖截至2026年5月29日当周的生物制药行业的商业动态。本期节目采用人工智能文本转语音及语音仿真技术制作。 本期要闻: GLP-1受体激动剂能否辅助抗癌；诺华公司的心血管战略；礼来公司的雷塔鲁肽在肥胖症治疗方面前景可期；礼来公司加大对细胞与基因疗法的投入；以及中国新数据保护法规对商业领域的影响。 Story links: https://insights.citeline.com/scrip/podcasts/scrips-five-must-kn...

Interventional cardiologist and Soley Therapeutics CEO Yerem Yeghiazarians joins In Vivo’s David Wild to unpack how decoding cell stress with live‑cell imaging and AI is driving a new oncology pipeline, and what it takes to build a platform‑plus‑pipeline biotech while still practicing medicine.

Pink Sheet Executive Editor Derrick Gingery, Senior Editor Sue Sutter and Editor-in-Chief Nielsen Hobbs consider the potential impact a mandated nondisclosure agreement could have on US Food and Drug Administration activities and its employees (:34), as well as the changes the agency’s hiring push caused to user fee reauthorization efforts (13:50). More On These Topics From The Pink Sheet Proposed...

Audio roundup of selected biopharma industry content from Scrip over the business week ended May 22, 2026. This episode was produced with the help of AI text-to-voice and voice emulation tools. This time – industry grapples with MFN fallout; rapid early trials fuel China deals; AbbVie looks to grow in neuroscience; is circular DNA the next big thing?; and a flunk for Regeneron’s fianlimab. Story l...

"Biotechs are running increasingly complex clinical trials with lean teams, tight budgets, and growing pressure to deliver faster results. In this episode, Claire Riches, VP, Clinical Solutions, Citeline is joined by Carrie Melvin, Head of Clinical Operations and Data Management, Lantheus to explore how smarter outsourcing, stronger CRO partnerships, and patient‑focused trial design can improve ex...

本期播客内容来自《Scrip》杂志，精选内容涵盖截至2026年5月22日当周的生物制药行业的商业动态。本期节目采用人工智能文本转语音及语音仿真技术制作。 本期要闻: 行业正努力应对最惠国待遇政策带来的影响；早期临床试验进展迅速推动中国市场合作；艾伯维（AbbVie）寻求在神经科学领域扩张；环状DNA会是下一个重大突破吗？；以及Regeneron公司的fianlimab遭遇挫折。 Story links: https://insights.citeline.com/scrip/podcasts/scr...

Pink Sheet Executive Editor Derrick Gingery, Senior Reporter Maaisha Osman, Senior Editor Sue Sutter and Editor-in-Chief Nielsen Hobbs discuss the impact of the US Food and Drug Administration’s purge of multiple center directors and other senior executives in the wake of Commissioner Martin Makary’s resignation (:34). They also discuss the agency’s potential new direction and the initial comments...

MHRA’s Rob Reid spoke to Ashley Yeo at MTF 2026 on issues affecting UK and Great Britain medtech regulation

As global clinical development strategies evolve, Europe is emerging as a critical hub for scientific innovation, operational agility, and patient recruitment — reshaping its role in the future of clinical trials. In this episode, Scott Davis, Vice President of Clinical Services at Novotech, joins Andrew Warmington from Citeline to explore how sponsors are rethinking Europe’s place in global devel...

Ovid Therapeutics Chairman Jeremy Levin talks with Scrip about how the US should view its biotech sector as a strategic national asset and urges the venture capital sector to place more emphasis on supporting early and innovative science.

本期播客内容来自《Scrip》杂志，精选内容涵盖截至2026年5月15日当周的生物制药行业的商业动态。本期节目采用人工智能文本转语音及语音仿真技术制作。 本期要闻: 葛兰素史克（GSK）强化下游肥胖症战略；诺和诺德（Novo）在早期肥胖症口服药市场占据优势； 罗氏对瑞士的支持面临压力；恒瑞与百时美施贵宝达成重大研发联盟；PCSK9药物Lerochol在美国以更低的直接成本上市。 Story links: https://insights.citeline.com/scrip/podcas...

Audio roundup of selected biopharma industry content from Scrip over the business week ended May 15, 2026. This episode was produced with the help of AI text-to-voice and voice emulation tools. This time – GSK bolsters downstream obesity strategy; Novo winning early obesity pill market; Roche’s support for Switzerland under strain; Hengrui and BMS strike huge R&D alliance; PCSK9 drug Lerochol laun...

Pink Sheet Executive Editor Derrick Gingery, Senior Reporter Maaisha Osman, Senior Editor Sue Sutter, Editor-in-Chief Nielsen Hobbs, as well as special guest Mike McCaughan, founding member of Prevision Policy, discuss the circumstances and mistakes that lead to Martin Makary’s resignation as head of the US Food and Drug Administration (:38), his achievements during his short term (21:56), the age...

The MHRA’s spring 2026 CE-marking consultation, the progress of UK medtech statutory instruments and the European Commission’s proposed revision of the MDR and IVDR were top of mind for the Association of British HealthTech Industries' Steve Lee as he did the rounds – and the panels – at the MedTech Forum 2026.

Generics Bulletin's editorial team discusses the recent Medicines for Europe biosimilars conference, attended by deputy editor Dean Rudge; while editor Dave Wallace talks about the latest big deals in biosimilars and what is behind them.

Kurma Partners has closed BioFund IV at €215m — its largest fund to date, but roughly €35m short of its initial target. For partner Amanda Gett-Chaperot, that gap is more than a fundraising footnote: it points to a structural problem that has long constrained European biotech's ability to build at US scale. Tags: Venture capital, European biotech, Fundraising, Exits, Early-stage investment

Arcutis Biotherapeutics' CEO Frank Watanabe joins In Vivo’s David Wild to talk about building a patient‑first culture and turning a three‑person startup into a commercial‑stage immunodermatology company. He explains how Zoryve (roflumilast) is reshaping care in chronic inflammatory skin diseases, why Arcutis is pushing beyond dermatology offices into primary care and pediatrics, and how new assets...